Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx Submit Nexavar sNDA For Liver Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.

You may also be interested in...



Bayer/Onyx’s Nexavar Gets Liver Cancer Indication

Sorafenib becomes first systemic drug therapy approved for unresectable HCC.

Bayer/Onyx’s Nexavar Gets Liver Cancer Indication

Sorafenib becomes first systemic drug therapy approved for unresectable HCC.

As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions

Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel